A498 CDX Model

The A498 cell line is derived from human renal cell carcinoma (RCC), typifying the clear cell subtype, which is the most prevalent form of RCC. A498 serves as an instrumental model for understanding RCC biology, its underlying molecular pathways, and for evaluating potential therapeutic strategies. This cell line exhibits several molecular features and genetic alterations that mirror the clinical attributes seen in RCC patients, rendering it highly representative for preclinical studies. The in vitro and in vivo behavior of A498 provides insights into RCC’s unique growth patterns, metastatic potential, angiogenesis, and response to therapies. Researchers utilize A498 to uncover pivotal aspects of RCC pathogenesis and to probe, test, and refine novel treatment modalities, particularly in the landscape of targeted therapies and immunotherapies.

Model Details

Cancer Location: Kidney
Cancer Type: Renal Cell Carcinoma
Model Name: A498
Mouse Strain: Nu/Nu
Treatment Data Available: Chemotherapy (Pazopanib)

A-498 Growth curves: Repsonse to Pazopanib

A498 CDX Model

Growth of subcutaneous A-498 in Nu/Nu mice (n=9-12)

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.